April 20, 2017
Mylan launches its generic schizophrenia drug
Mylan has launched of Perphenazine Tablets USP, a generic version of Schering’s Trilafon Tablets 2 mg, 4 mg, 8 mg and 16 mg.
Pharmaceuticals, Biotechnology and Life Sciences
Category: North America
April 20, 2017
Diplomat to sell Tesaro’s cancer drug
Diplomat Pharmacy will distribute Zejula (niraparib) for women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
April 19, 2017
Cannabidiol may reduce difficult to control seizures
A study showed that cannabidiol shows great promise in that it may reduce seizures that are otherwise difficult to control.
April 19, 2017
Matinas BioPharma welcomes Dominick DiPaolo as Senior VP of Quality and Regulatory Compliance
Matinas BioPharma Holdings, a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, has appointed Dominick DiPaolo as Senior Vice President of Quality and Regulatory Compliance.
April 18, 2017
FDA nods for Verona’s inhibitor trial
Respiratory diseases biopharmaceutical specialist, Verona Pharma said Tuesday that the U.S. Food and Drug Administration has given the green light for the kick-start of a pharmacokinetic (PK) clinical trial in the U.S. for its RPL554 candidate, with the acceptance of an Investigational New Drug application (IND).
April 18, 2017
DermTech partners with two pharmaceutical companies
DermTech, Inc., a player in non-invasive molecular dermatology, has entered into two collaborations with multi-national pharmaceutical companies,
April 13, 2017
Diplomat in a deal with Corizon Health
Diplomat Pharmacy and Corizon Health have entered into three-year agreement according to which Diplomat will provide pharmacy services and dispense limited-distribution specialty drugs for Corizon Health’s clients and support its in-house mail-order pharmacy, PharmaCorr
April 12, 2017
Respira Therapeutics, United Therapeutics Corporation join to fight pulmonary hypertension
Respira Therapeutics, a privately held pharmaceutical company developing innovative inhaled therapies to treat pulmonary hypertension and other pulmonary diseases, has entered into a strategic collaboration with United Therapeutics Corporation for the development and exclusive license of Respira’s inhaled drug-device product, RT234, for pulmonary hypertension indications in North America.
April 12, 2017
Roche to launch new biomarker for prostate cancer diagnosis
Roche has announced the global launch of the anti-p504s (SP116) Rabbit Monoclonal Primary Antibody2 for prostate cancer diagnosis.
April 12, 2017
Active Biotech wins FDA’s Orphan Drug Designation for its multiple myeloma drug
U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Active Biotech for its investigational novel agent tasquinimod, for the treatment of multiple myeloma.